The stock of Merus N.V (MRUS) has seen a 3.40% increase in the past week, with a -5.40% drop in the past month, and a -5.80% decrease in the past quarter. The volatility ratio for the week is 3.36%, and the volatility levels for the past 30 days are at 3.18% for MRUS. The simple moving average for the last 20 days is -0.47% for MRUS stock, with a simple moving average of 13.06% for the last 200 days.
Is It Worth Investing in Merus N.V (NASDAQ: MRUS) Right Now?
Additionally, the 36-month beta value for MRUS is 1.12. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for MRUS is 59.23M and currently, short sellers hold a 11.20% ratio of that float. The average trading volume of MRUS on September 20, 2024 was 608.29K shares.
MRUS) stock’s latest price update
Merus N.V (NASDAQ: MRUS)’s stock price has plunge by 2.81relation to previous closing price of 49.42. Nevertheless, the company has seen a 3.40% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-14 that Merus NV has seen a significant increase in market cap from $852mn to $3.46bn in the past year. Merus is a leader in developing multispecific antibodies with promising lead candidates petosemtamab and zenocutuzumab targeting various cancers. Merus has strong financials, and partnerships with major companies like Gilead, Incyte, and Eli Lilly, but faces risks due to its current valuation and assumptions about pipeline success.
Analysts’ Opinion of MRUS
Many brokerage firms have already submitted their reports for MRUS stocks, with Truist repeating the rating for MRUS by listing it as a “Buy.” The predicted price for MRUS in the upcoming period, according to Truist is $69 based on the research report published on March 28, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see MRUS reach a price target of $65, previously predicting the price at $42. The rating they have provided for MRUS stocks is “Buy” according to the report published on March 04th, 2024.
Canaccord Genuity gave a rating of “Buy” to MRUS, setting the target price at $45 in the report published on November 02nd of the previous year.
MRUS Trading at -3.33% from the 50-Day Moving Average
After a stumble in the market that brought MRUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.53% of loss for the given period.
Volatility was left at 3.18%, however, over the last 30 days, the volatility rate increased by 3.36%, as shares sank -5.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.98% lower at present.
During the last 5 trading sessions, MRUS rose by +3.40%, which changed the moving average for the period of 200-days by +102.19% in comparison to the 20-day moving average, which settled at $50.91. In addition, Merus N.V saw 84.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRUS starting from Shuman Harry, who sale 2,500 shares at the price of $54.00 back on Aug 21 ’24. After this action, Shuman Harry now owns 7,002 shares of Merus N.V, valued at $135,000 using the latest closing price.
Shuman Harry, the VP Controller, PAO of Merus N.V, sale 2,500 shares at $54.00 during a trade that took place back on Aug 20 ’24, which means that Shuman Harry is holding 7,002 shares at $135,000 based on the most recent closing price.
Stock Fundamentals for MRUS
Current profitability levels for the company are sitting at:
- -5.13 for the present operating margin
- -1.05 for the gross margin
The net margin for Merus N.V stands at -4.76. The total capital return value is set at -0.22. Equity return is now at value -33.39, with -26.70 for asset returns.
Based on Merus N.V (MRUS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -9.17. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -14.43.
Currently, EBITDA for the company is -154.01 million with net debt to EBITDA at 3.46. When we switch over and look at the enterprise to sales, we see a ratio of 80.91. The receivables turnover for the company is 9.04for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.97.
Conclusion
In conclusion, Merus N.V (MRUS) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
